Table 2.
Characteristics of the study population before CCM implantation
| Characteristic | Value |
|---|---|
| Age, y | 54.3 ± 11.5 |
| Male sex | 18 (90) |
| Weight, kg | 103.5 ± 23.7 |
| BMI, kg/m2 | 32.5 ± 7.2 |
| SBP, mm Hg | 118.2 ± 15.7 |
| LVEF, % | 24.4 ± 8.1 |
| DM | 4 (20) |
| CKD | 8 (40) |
| Current smoker | 8 (40) |
| Chronic lung disease | 7 (35) |
| QRS width, ms | 108.9 ± 19.4 |
| HF etiology | |
| Ischemic | 7 (35) |
| DCM | 13 (65) |
| NYHA class | |
| II | 3 (15) |
| III | 16 (80) |
| IV | 1 (5.0) |
| Medications | |
| ACEI/ARB | 20 (100) |
| β‐Blocker | 19 (95) |
| MRA | 17 (85) |
| Ivabradine | 4 (20) |
| Diuretic | 20 (100) |
| Amiodarone | 4 (20) |
| Cr, mg/dL | 1.37 ± 0.83 |
| NT‐proBNP, pg/mL | 2882.7 ± 5456.6 |
| ICD indication | |
| Primary preventive | 16 (80) |
| Secondary preventive | 4 (20) |
| Patients with former transvenous ICDs | 6 (30) |
Abbreviations: ACEI, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CCM, cardiac contractility modulation; CKD, chronic kidney disease; Cr, creatinine; DCM, dilated cardiomyopathy; DM, diabetes mellitus; HF, heart failure; ICD, implantable cardioverter‐defibrillator; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist; NT‐proBNP, N‐terminal pro brain natriuretic peptide; NYHA, New York Heart Association; SBP, systolic blood pressure; SD, standard deviation.
Data are presented as n (%) or mean ± SD.